The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …

Before 2009, nonsmall cell lung cancer (NSCLC) was one disease entity treated by cytotoxic
chemotherapy that provided a response rate of 20–35% and a median survival time (MST) of …

Background: A phase III trial was conducted to compare the safety and efficacy of erlotinib
with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth …

Key “driver” mutations have been discovered in specific subgroups of non-small-cell lung
cancer (NSCLC) patients. Activating mutations in the form of deletions in exon 19 (del 19) or …

PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

9001 Background: Standard first-line therapy for EGFR mutant advanced non-small cell lung
cancer (NSCLC) is an EGFR-directed oral TKI. We evaluated whether adding pemetrexed …

Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …

Abstract On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for
the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors …

Epidermal growth factor receptor (EGFR) gene mutations are frequent in lung cancer arising
in patients of Asian ethnicity, female sex, nonsmokers, and adenocarcinoma histology …

Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …